Equities Analysts Offer Predictions for BioNTech Q1 Earnings

BioNTech SE (NASDAQ:BNTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of BioNTech in a research note issued on Thursday, June 5th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($2.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.33) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at $0.90 EPS and FY2026 earnings at ($4.46) EPS.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 earnings per share.

A number of other research firms also recently weighed in on BNTX. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. Morgan Stanley lowered their target price on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Citigroup reiterated a “buy” rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.25.

BioNTech Stock Performance

Shares of BNTX stock opened at $108.49 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company’s fifty day moving average price is $99.26 and its two-hundred day moving average price is $108.40. The firm has a market capitalization of $26.08 billion, a P/E ratio of -51.66 and a beta of 1.29.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. Daiwa Securities Group Inc. lifted its holdings in shares of BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after buying an additional 128 shares during the last quarter. Bank of New York Mellon Corp lifted its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Probity Advisors Inc. boosted its holdings in BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in BioNTech by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock valued at $227,000 after buying an additional 209 shares during the last quarter. Finally, Midwest Professional Planners LTD. grew its stake in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock worth $462,000 after acquiring an additional 222 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.